CVS Health Corporation (CVS) stock analysis
Company overview and business model
Source fact: CVS Health Corporation provides health solutions in the United States. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services, including medical, pharmacy, dental, and behavioral health plans; medical management capabilities; Medicare Advantage and Medicare Supplement plans; prescription drug plans (PDPs); and Medicaid health care management services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The Health Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, specialty and mail-order pharmacy, clinical services, disease management, medical spend management services, and pharmacy and other administrative services. It serves employers, insurance companies, unions, government employee groups, health plans, PDPs, Medicaid managed care plans, CMS, plans offered on public health insurance exchanges, and other sponsors of health benefit plans. The Pharmacy & Consumer Wellness segment sells prescription and over-the-counter drugs, consumer health and beauty products, personal care products, and other general merchandise products. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to care facilities and other care settings. It operates online retail pharmacy websites, retail specialty pharmacy stores, and compounding pharmacies, as well as branches for infusion and enteral nutrition services. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was founded in 1963 and is headquartered in Woonsocket, Rhode Island.
Classification: NYSE · Healthcare · Healthcare Plans
Revenue and growth
Source fact: Revenue was USD 402.07 billion for the period ending 2025-12-31.
Caverian calculation: Revenue changed +7.8% (FY2025 vs FY2024).
Profitability
Source fact: Net income was USD 1.77 billion in the latest reported period.
Source metric: Reported net margin was 0.4%.
Balance sheet and liquidity
Source fact: Cash and equivalents were USD 8.45 billion.
Source fact: Total debt was USD 79.95 billion.
Source metric: Current ratio was 0.84x.
Cash-flow analysis
Source fact: Operating cash flow was USD 10.64 billion.
Source fact: Free cash flow was USD 7.81 billion.
Valuation
Source metrics: Trailing P/E 24.77x; Forward P/E 11.04x; Price to book 1.51x; Price to sales 0.29x; EV/EBITDA 10.93x.
Caverian model output: Value score was 63/100.
Competitive position
Classification: Peer context: Healthcare Plans within Healthcare.
Caverian model output: Quality score was 51/100.
Caverian model output: Growth score was 42/100.
Material risks
Caverian model interpretation: Watch out: short-term cash may not cover short-term bills.
Caverian calculation: Altman Z-score was 2.33 (grey zone).
Caverian calculation: Piotroski F-score was 6/9.
Data sources and freshness
Freshness: This report uses a stored upstream snapshot; statement periods are shown alongside the figures.
Methodology and limitations
Facts reproduce stored upstream fields. Calculations derive only from the displayed stored statements. Model outputs are Caverian interpretations, not investment advice or a buy/sell recommendation.
How Caverian approaches valuation · Sources and product principles